Filter by topic:

FTC Files Brief in Support of Private Antitrust Case Against Makers of Parkinson’s Drug

The Federal Trade Commission recently filed an amicus brief in support of a generic drug maker’s antitrust case involving Apokyn®, a drug developed ...


Fifth Circuit Upholds FTC Finding: Impax Lab's Reverse Payment Scheme Was Illegal

Citing “more than enough evidence," the U.S. Court of Appeals for the Fifth Circuit has upheld the Federal Trade Commission’s determination that ...

April 28, 2021
, ,

Healthcare Industry Antitrust Measures Advance as Pandemic Pressures Persist

California Attorney General Xavier Becerra says the COVID-19 virus has “shone a light” on the impact consolidation in the healthcare market has had ...

, , ,

Class of End-Payors Certified in Illegal Monopolization Suit Against Drug Maker Allergan

On May 5, 2020, U.S. Judge Nina Gershon of New York granted certification to a class of end-payor plaintiffs (EPPs) who purchased the successful ...

, , ,

FTC, FDA Team Up Against Anticompetitive Tactics in Biological Product Industry

Anticompetitive conduct and misleading advertising practices in the burgeoning biosimilars market – where nearly identical versions of bioilogics are ...

February 28, 2020
, , , ,

Agencies’ Antitrust Suit Against Drug Maker Underscores Challenges of Bringing Biosimilars to Market

The Federal Trade Commission and the New York Attorney General have sued Vyera Pharmaceuticals and two of its executives for antitrust law ...

February 05, 2020
, , , , ,

FTC Challenges Illumina- PacBio Merger Over Next Gen DNA Sequencing

The Federal Trade Commission (FTC) is challenging Illumina Inc.'s $1.2 billion acquisition of Pacific Biosciences of California Inc. (PacBio), ...

December 18, 2019
, , , , ,

Undeterred by Challenges, Google Makes Another Move to Harvest Healthcare Data

You have to give Google credit. It’s no quitter. Despite pressure in the United States and Europe that might tell other companies to take a breath, ...

December 06, 2019
, , , ,

Billion-Dollar Merger of DNA Sequencing Firms Opposed by U.K., Questioned in U.S.

DNA sequencing giant Illumina, Inc.’s proposed $1.2 billion acquisition of Pacific Biosciences of California Inc. has drawn opposition in the U.K. ...

November 05, 2019
, , ,

California Tackles Big Pharma’s Anticompetitive ‘Pay for Delay’ Practices That Slow Down Lower-Cost Generic Drug Development

California Gov. Gavin Newsom has signed AB 824, known as the “Pay-for-Delay" bill, blocking pharmaceutical companies from paying generic drug makers ...


Consumer Groups, Unions to FTC: AbbVie-Allergen Merger Will Deny Access to More Effective and Affordable Drugs

In a September 13, 2019 letter, seventeen consumer advocacy groups and unions (led by Public Citizen Inc.) sent a clear message to the Federal Trade ...


Legislators Call Remedies for Drug Industry Antitrust Conduct Ineffective

Democrats and Republicans in both chambers of Congress have come out against drug industry practices such as paying generic drug companies to delay ...

Subscribe to the MoginRubin blog

Sign up to start receiving our blog posts straight to your inbox.

Thank You!

Check your inbox for details about your MoginRubin Blog subscription.